别嘌呤醇与芬兰人群队列中前列腺癌生存的关系
该研究基于芬兰前列腺癌筛查随机研究(FinRSPC)队列,纳入1996—2015年新诊断的9252例前列腺癌患者,分析别嘌呤醇使用与前列腺癌特异性生存(CSS)和总生存(OS)的关系。中位随访9.86年期间共2942例死亡,其中883例死于前列腺癌。别嘌呤醇使用者与非使用者的CSS无差异,但使用者OS较低(多变量校正HR 1.77;95%CI:1.57-2.00),且OS降低随别嘌呤醇使用强度增加而减弱。
要点
- 别嘌呤醇使用者与非使用者的前列腺癌特异性生存无差异。
- 别嘌呤醇使用者总生存较低,多变量校正HR 1.77(95%CI:1.57-2.00)。
- 总生存降低随别嘌呤醇使用强度增加而减弱,但按使用时长或强度无显著差异。
核心结论
- 别嘌呤醇使用与前列腺癌特异性生存无显著差异,但使用者总生存较低。
- 别嘌呤醇可能对前列腺癌无抗癌作用,而可能是导致前列腺癌男性总生存缩短的代谢问题的替代标志。
研究设计与样本
- 研究队列最初纳入芬兰前列腺癌筛查随机研究(FinRSPC),包含1996—2015年新诊断的前列腺癌病例,共9252名男性。
- 别嘌呤醇购买信息来自芬兰社会保险机构全国处方登记处,死亡、治疗和其他药物使用信息来自登记处,肿瘤分期和诊断时PSA来自病历。
- 随访从诊断开始,分别分析前列腺癌特异性死亡和全因死亡两个终点,采用扩展Cox回归校正诊断时年龄、Charlson合并症指数、FinRSPC试验组、其他药物使用和EAU前列腺癌风险组。
主要发现
- 中位随访9.86年期间共发生2942例死亡,其中883例死于前列腺癌。
- 别嘌呤醇使用者与非使用者的前列腺癌特异性生存无差异。
- 别嘌呤醇使用者总生存较低,多变量校正风险比1.77(95%CI:1.57-2.00)。
- 总生存降低随别嘌呤醇使用强度增加而减弱,但按使用时长或强度无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allopurinol is gout medication that inhibits uric acid formation. Its possible anti-carcinogenic properties have been under research in past years. Studies based on Taiwanese registries showed that long term allopurinol use might reduce prostate cancer (PCa) incidence. However, our studies based on Finnish registries did not support those findings. In this study, we evaluate whether allopurinol use is associated with prostate cancer-specific survival (CSS) or overall survival (OS) in a Finnish population-based cohort. METHODS: The study cohort was originally enrolled for the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). We included all newly diagnosed PCa cases during 1996-2015, 9252 men in total. Information on allopurinol purchases was from the national prescription registry of the Social Insurance Institution of Finland. Information about deaths, treatments, and use of other medications was obtained from registries, and tumor stage and PSA at diagnosis from medical records. Follow-up started at diagnosis, and we analysed separately two endpoints: PCa-specific death and overall death. We used an extended Cox regression with adjustment for age at diagnosis, Charlson comorbidity index, FinRSPC trial arm, use of other drugs and EAU PCa risk group. RESULTS: During a median follow-up of 9.86 years, 2942 deaths occurred, including 883 from PCa. There was no difference in CSS between allopurinol user and non-users, but allopurinol users had lower OS (multivariable-adjusted hazard ratio 1.77; 95% CI: 1.57-2.00). However, this decrease in OS was mitigated along with increasing intensity of allopurinol use. CONCLUSIONS: We found no marked difference in CSS by allopurinol use. Allopurinol users had lower OS but there were no significant differences by duration or intensity of allopurinol use. Allopurinol use may not have anticancer effects against prostate cancer; instead, it may be a surrogate for metabolic problems causing shorter OS among men with PCa.
引用
- Kukko V, Kaipia A, Talala K, et al. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2022. PMID: 36131010. doi:10.1038/s41391-022-00597-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。